Introduction
Fas is a member of the tumor necrosis factor receptor (TNFR) family. It consists of an extra cellular domain with cysteine-rich repeats and a cytoplasmic tail containing a death domain (1, 2) . Fas clustering recruits the Fas-associated death domain (FADD) adapter protein and forms the death-inducing signalling complex (DISC), causing the activation of caspase-8 (3). FADD is known mainly for its death receptor adaptor function at the cell membrane (4) (5) (6) . FADD has also been shown to regulate cell proliferation in addition to its function in apoptosis (3) .
The human FADD protein contains 208 amino acids, and its molecular weight is approximately 27 kDa. FADD has the trend of aggregation and thus tends to form insoluble inclusion bodies during its expression in Escherichia coli (7) . Recently, the structure of hFADD (residues 1-191) in solution was well revealed by NMR. A point mutation Phe 25 → Tyr was introduced to suppress the self-aggregation of FADD. Recently increasing evidence showed that absent or low FADD expression was found in different types of tumor cells and was a prognostic factor for poor response to chemotherapy (9, 10) . The above findings suggest that FADD detection tool of FADD protein is indispensable for the extensive purpose and for further investigating the biological and clinic significance and mechanism of human FADD protein.
The present paper described the expression of recombinant human FADD protein in Escherichia coli. Recombinant FADD was expressed as a polyhistidine fusion protein and purified by one step Ni 2+ affinity chromatography under denatured condition. After optimization of its expression and purification, polyclonal antibody against human FADD was produced, its application in immunoassays was carefully characterized. All the studies indicated that FADD antibody produced in the present study is applicable to various immunodetection of human FADD protein.
Materials and Methods

Animals and cell lines
Three-month-old healthy, parasite-and disease-free New Zealand white rabbits used for polyclonal antibody production were purchased from the Centre for Animal Breeding, Nanjing Agricultural University. All experimental protocols were in accordance with the requirement of the Animal Care and Ethics Committee, College of Life Sciences, Nanjing University, and animal studies were conducted with high standard. Human embryonic kidney 293 cell (HEK 293) was obtained from the Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences and cultured in DMEM medium supplemented with 1 The State Key Laboratory of Pharmaceutical Biotechnology and Jiangsu Center of Hepatobiliary Diseases, Nanjing University, Nanjing 210093, China; 10% fetal calf serum at 37°C in 5% CO 2 .
Recombinant plasmid construction and cell transfections
The pCDNA 3.1-hFADD plasmid containing human FADD coding sequence was previously constructed in our lab by Dr. Jian-Qiang Ye (11 
Expression of human FADD fusion proteins
His-tagged human FADD was expressed as inclusion bodies in E. coli BL21 (DE3) cells (Novagen, Madison, WI, USA). A single colony transformed with pET28a His-FADD plasmid was grown overnight at 37C in 20 ml of LB medium containing 50 g/ml kanamycin. The culture was then inoculated into 1 L of fresh liquid LB medium containing 50 g/ml kanamycin and once the cells reached an A 600 of 0.9-1.0, expression of human FADD was induced at 37C for an additional 4 h by adding IPTG to a final concentration of 0.6 mM. The cells were pelleted by centrifugation at 6,000 rpm at 4C for 10 min.
Purification of human FADD fusion proteins by a denatured method
The bacterial pellet was re-suspended in a volume of 40 ml buffer A (50 mM sodium phosphate buffer, pH 8.0, 150 mM NaCl, 1 mM PMSF) and ultrasonicated for 15 min on ice. The insoluble fraction was washed with buffer B (50 mM sodium phosphate buffer, pH 8.0, 150 mM NaCl, 1% Triton X-100) by stirring with the magnetic agitator for 2 h. After centrifugation for 20 min at 12,000 rpm and 4C, the pellet of inclusion bodies was re-suspended in 40 ml buffer C (50 mM sodium phosphate, pH 8.0, 150 mM NaCl, 8 M urea) and dissolved by ultrasonic liquid processor (Sonic Dismembrator 550, Fisher Scientific, USA) for 15 min, followed by centrifugation ( 12,000 rpm, 20 min, 4C). The supernatant was added to the Ni 2+ affinity column (1.6 cm × 5 cm) (Sigma, St, Louis, USA) equilibrated with buffer C. The Ni 2+ column was washed with buffer D (50 mM sodium phosphate, pH 8.0, 20 mM imidazole, 150 mM NaCl) to remove nonspecific binding proteins. The His6-tagged fusion protein (human FADD) was eluted with buffer E (50 mM sodium phosphate, pH 8.0, 500 mM imidazole, 150 mM NaCl). Refolded human FADD was produced by drop-wise adding the denatured human FADD into 0.5 L of refolding buffer (20 mM Tris-HCl, pH 8.0, 10% sucrose, 1 mM EDTA) over the period of 3-4 h at room temperature. The final urea concentration in the refolding buffer was 0.16 M. The remaining urea and imidazole were removed by ultrafiltration using Amicon 8200 stirred cell (Amicon, Millipore, Bedford, MA, USA) with Amicon YM10 membrane (cut off = 10,000). At least three dilution/concentration steps were performed at 4C. The final product was stored in multiple aliquots and frozen at -80C. Protein concentration was determined by Bradford method. The total bacterial protein and purified human FADD were analyzed by 12% SDS-PAGE.
Anti-FADD antibody production
Prior to a course of immunizations, a 2-3 ml of test bleed was taken from the rabbit to provide a source of preimmune antiserum. The human FADD protein containing 500 g was mixed with the Freund's adjuvant according to the manufacturer's instructions to achieve a final volume of 0.5 ml/injection. Keeping the syringe horizontal, 300 l of PBS solution which contained the human FADD was carefully introduced to the barrel of the syringe, and the plunger was inserted. Next, 200 l of Freund's adjuvant was drawn into a 1-ml syringe and transferred into the needle end of a second 3-ml syringe. The two plungers were pushed alternatively to mix the components of the two syringes. This mixture was injected subcutaneously into the neck region of the rabbit. A total of four injections of renatured FADD protein in Freund's adjuvant were performed at days 0, 14, 28 and 56 before final bleeding was taken at day 90.
Purification of anti-FADD IgG
Before affinity separation of IgG, protein A-agarose was washed twice with IgG binding buffer to remove sodium azide. To 270 l of washed protein A-agarose beads, 30 l of IgG or plasma samples were added. The contents were mixed and incubated at room temperature (RT) for 10 min for antibody binding. The agarose resin was washed twice with binding buffer (10 mM Tris, pH 7.5) to remove unbound components. The agarose resin was eluted with 300 l of elution buffer (0.1 M glycine buffer, pH 2-3); the eluent was collected and immediately neutralized to physiological pH by adding 1.0 M Tris, pH 7.5. Antibody solution was adjusted to 1 mg/ml, which is an ideal concentration for its stability and for many practical applications. Purified antibody was stored at -20°C with 0.02% sodium azide (12) .
Western blot analysis
For Western blot experiments, HEK 293 cells transfected with pcDNA-hFADD plasmid were lysed with 0.5 ml of lysis buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% Nonidet P-40, and 0.5% sodium deoxycholate) on ice for 30 min. Insoluble material was removed by centrifugation for 10 min at 12,000 g at 4°C. The supernatants were collected, their protein concentrations were measured using the Bradford method and 30 g lysates were used for Western blot detection. Protein extracts from HEK 293 cells were separated by 15% SDS-PAGE and then electrophoretically transferred to nitrocellulose membranes (Hybond C, Amersham, USA). Membranes were blocked with 5% non-fat milk for 1 h and then incubated with anti-FADD (1.0 Volume 5 Number 6 December 2008 g/ml) polyclonal antibody for 1 h at room temperature. Then membrane was washed three times with phosphate buffered saline Tween-20 (PBST) and followed by incubation for 1 h with HRP conjugate of goat anti-rabbit IgG (0.2 g/ml; Santa Cruz Biotechnology Inc, USA). The membrane was washed and then developed with enhanced chemiluminescence reagent (Amersham Life Science Inc., USA) by exposure to Kodak X-Omat Blue film (NEN life science Products, USA).
Immunofluorescence assay HEK 293 cells were grown in DMEM (HyClone, USA) supplemented with 10% FBS (Hyclone, USA), penicillin, and streptomycin. Cells were transiently transfected with pcDNA-hFADD by the standard calcium phosphate method at 24 h after mounting on glass cover slip. At 48 h posttransfection, cells were fixed with 4% paraformaldehyde and permeabilized with 0.2% Triton X-100 for 5 min, and blocked with 3% BSA in PBS for 1 h. After 1-h incubation with 1/100 diluted rabbit anti-FADD polyclonal antibody, cells were then incubated with Cy3-conjugated anti-rabbit IgG (Sigma, USA) for 1 h. As a control, cells incubated with 3% BSA in PBS, without rabbit anti-FADD polyclonal antibody. Nuclei were counterstained with 4, 6-diamidino 2-phenylindole (DAPI). Images were acquired and processed using AxioVision 3.1 software on Carl Zeiss Axioplan 2.
Results and Discussion
In this study, we described the expression and purification of a recombinant human FADD protein as well as the production and characterization of the antiserum directed from the refolded human FADD protein.
The entire open reading frame of the human FADD from pcDNA 3.1-hFADD was sub-cloned into pET28a plasmid (Novagen, Madison, WI, USA). E. coli BL21 (DE3) strain transformed with this recombinant vector allowed the expression of a large amount of His-FADD fusion protein.
His-FADD protein, however, was highly insoluble and the majority was found in the post-sonication pellets. This insolubility has already been noticed for other FADD proteins expressed in E. coli (13) . The addition of 8 M urea prior to sonication solubilized most of the protein. Refolded human FADD was produced by drop-wisely adding the denatured human FADD into refolding buffer, and the final urea concentration in the refolding buffer was 0.16 M. The yield of purified protein was estimated at 23 mg/L of culture for the denatured His-FADD fusion protein. The use of 8 M urea markedly increased the amount of eluted protein ( Figure  1A ). Extensive dialysis of the protein against refolding buffer was then necessary to remove the excess urea for proper refolding of the human FADD protein. This step, however, resulted in a slow protein precipitation.
After SDS-PAGE analysis, there was an obviously homogenous band corresponding to molecular weight (MW) of around 31 kDa, which is consistent with the expected MW of His-FADD fusion protein ( Figure 1A ), as compared with the bacteria containing empty vector (data not shown). Finally, denatured FADD was refolded by the dilution method and used for immunizing rabbits.
Anti-FADD polyclonal serum was generated by repeated immunization of rabbits with full-length human FADD protein (14) . Titration of antiserum was performed by ELISA assay with purified FADD-protein coated onto microplates. A high titre of anti-FADD antibodies was detected after the third injection. After final bleeding, serum was purified by protein A affinity resin; a total of 80 mg antibody was obtained from one rabbit with 90% purity, which was analyzed by SDS-PAGE ( Figure 1B) . In Figure 1B , there are two main protein bands observed in the gel, corresponding to the molecular weight of 56 kDa and 27 kDa respectively. The bands represent the heavy and light chain of IgG molecules.
In order to confirm the specificity of the purified antibodies, Western blot analysis carried out with the polyclonal antibody revealed a 28-kDa band which corresponds to FADD protein ( Figures 1C and 1D ). According to Figure 1D , endogenous FADD expression can be detected by anti-FADD polyclonal antibody. It will be specifically detected FADD due to FADD-deficient Jurkat cells did not exhibit the band. FADD antibodies, which are produced in our lab, also recognized FADD in other cell lines, In this article, it was described the productions of both recombinant human FADD and polyclonal antibody against human FADD with high specificity via a simple and cost-effective method. It will be of great application potential for various immunodetection of human FADD protein and for the investigation of FADD's function in physiological and pathological conditions.
